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objective. To estimate the independent effect of a single lower respiratory tract infection, urinary tract infection, or other healthcare-
acquired infection on length-of-stay and variable costs and to demonstrate the bias from omitted variables that is present in previous
estimates.
design. Prospective cohort study.
setting. A tertiary care referral hospital and regional district hospital in southeast Queensland, Australia.
patients. Adults aged 18 years or older with a minimum inpatient stay of 1 night who were admitted to selected clinical specialities.
results. Urinary tract infection was not associated with an increase in length of hospital stay or variable costs. Lower respiratory tract
infection was associated with an increase of 2.58 days in the hospital and variable costs of AU$24, whereas other types of infection were
associated with an increased length of stay of 2.61 days but not with variable costs. Many other factors were found to be associated with
increased length of stay and variable costs alongside healthcare-acquired infection. The exclusion of these variables caused a positive bias
in the estimates of the costs of healthcare-acquired infection.
conclusions. The existing literature may overstate the costs of healthcare-acquired infection because of bias, and the existing estimates
of excess costs may not make intuitive sense to clinicians and policy makers. Accurate estimates of the costs of healthcare-acquired infection
should be made and used in appropriately designed decision-analytic economic models (ie, cost-effectiveness models) that will make valid
and believable predictions of the economic value of increased infection control.
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Healthcare-acquired infections (HAIs) are thought to gen-
erate substantial economic burdens. Patient morbidity and
mortality risks are increased, hospital stay is prolonged, and
additional cash costs arise for consumable items used to treat
the infection.1-3 The risk of acquiring an infection is also
believed to increase with increased length of hospital stay.4,5
A recent review suggested that 10%-70% of HAIs are pre-
ventable6 with appropriate infection control. The decision to
invest in additional infection control programs should be
informed by the expected changes to both cost and health
outcomes, and only efficient (ie, cost-effective) strategies
should be used.7-10 Cost outcomes will change because of
increased expenditure on infection control and the cost sav-
ings of avoided cases of HAI. Health outcomes will change
(improve) because excess morbidity and mortality risks are
reduced. Although economic arguments for additional infec-
tion control programs have been made, few data on the costs
and health benefits of these programs have been published.11
These data are vital for decision makers who face an increas-
ing pressure to tackle the problem of HAI from politicians
and from journalists who regularly inform the public about
the dangers of HAIs, especially those caused by methicillin-
resistant Staphylococcus aureus.
Research-based models that describe the economics of ad-
ditional infection control programs therefore rely on valid
estimates of the independent effect of HAI on length of hos-
pital stay and cost, but it is difficult to make bias-free esti-
mates. An unadjusted comparison of the cost outcomes for
patients with HAI and for those without HAI is not useful
because of other differences, unrelated to HAI, between the
two groups. For example, those with HAI might have more
comorbid conditions and so might generate quite different
(greater) cost outcomes regardless of the type of HAI. The
challenge is to tease out the independent effect of HAI on
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cost outcomes by making allowances for all observable con-
founders. Haley1 and Graves and Weinhold12 review the ex-
isting methods of direct attribution and comparative attri-
bution. Direct attribution requires an expert reviewer to assess
the extra cost from HAI. This method has been criticized as
being subjective and not reproducible,13 and comparative at-
tribution studies have been preferred by the research com-
munity. Researchers undertaking comparative attribution
studies use data collected from a cohort of hospitalized pa-
tients and either (1) select a subset of infected patients who
are then matched with uninfected controls for variables
thought likely to affect cost outcomes (eg, age, sex, and co-
morbidities) or (2) build multivariable statistical regression
models that describe the relationship between HAI and cost
outcomes, while controlling for other factors thought likely
to affect cost outcomes.14 The disadvantage of matching is
that infected patients can only be matched to uninfected con-
trols for a limited number of variables. Matching more than,
say, 5 or 6 variables requires a substantial increase in the size
of the pool of controls, which makes the research process
costly and inefficient. Matching too few variables might cause
bias from “omitted variables” because important factors that
explain the variation in cost outcomes are excluded. The
source of the bias from omitted variables is described in
Appendix A. The consequence of this bias is that the cost
attributed to HAI is either overstated or understated, although
our belief before performing the analysis was that the bias
will be positive (ie, that the cost of HAI is overstated).15 If
case patients are subsequently excluded from the study to
match more variables (ie, to mitigate bias from omitted var-
iables), then a selection bias arises because not all case patients
have the same opportunity to be included in the comparison
of cost outcomes. Those undertaking matched cohort studies
are forced to trade bias from “omitted variables” with bias
from the selection of individuals and cannot escape both
sources of bias at the same time.
The use of statistical regression analysis for a cohort of
patients can avoid selection bias completely and presents an
opportunity to reduce bias from omitted variables. A correctly
specified statistical regression model will summarize the as-
sociation between the outcome variable (ie, length of stay or
cost) and the independent variables (ie, HAI and other ob-
servable factors that might explain variation in outcomes). A
statistical regression model might take the form of this equa-
tion:
LOSp f(HAI,other controls,u) ,
where LOS is the outcome we wish to explain (length of stay
in the hospital), HAI is occurrence of an infection (1 p
infection and 0 p no infection) and “other controls” rep-
resents all other factors (eg, age, sex, primary diagnosis, co-
morbidities, and underlying state of health) that we believe
are associated with the variation in length of stay across the
sample. The term u represents the “residuals” or “error terms”
that capture the residual variation in length of stay not ex-
plained by the independent variables (ie, HAI and “other
controls”). An important requirement for regression analysis
is that the residuals are evenly distributed around the fitted
regression line (ie, error terms are homoskedastic), and the
smaller the residuals, the better the model. A model like this
will completely avoid selection bias, because every individual
from the cohort can be included in the analysis, and it will
reduce bias from omitted variables, because many indepen-
dent variables can be included within the set called “other
controls.” It is better to control for confounding in the anal-
ysis stage (regression analyses) than in the design stage
(matching).
Another source of bias arises from the relationship between
the variables HAI and LOS. Although we know that HAI
increases the length of stay, there is good evidence4,5,16 that
length of stay also increases the risk of HAI. This reverse
causality, or feedback ( and ), inducesLoSp HAI HAIp LoS
a correlation between the error terms and the independent
variables, leading to biased estimates and tests of hypotheses.17
This problem is called “endogenous variables bias” and has
been discussed in the context of HAI.3,18 Graves and Wein-
hold12,19 describe the problem in detail and report preliminary
attempts at a solution, using an instrumental variables
method. Controlling bias from endogenous variables and in-
terpreting the results of an unbiased model is a methodo-
logical challenge for future research.
The impact of different types of HAI on cost outcomes
has been studied since the 1950s, when Clarke et al.20 inves-
tigated whether S. aureus in surgical wounds extended the
length of stay of patients admitted to an English hospital.
Since then, studies using different methods of estimating costs
have produced quite different results. Direct attribution
methods have reported 3.7, 0.6, and 5.7 days of extra hos-
pitalization due to lower respiratory tract infection (LRTI),
urinary tract infection (UTI), and HAIs at other sites (here-
after, “other HAIs”), respectively,2 and an extra cost of US
$589 for a case of UTI.21 Studies with a matched-cohort design
have produced larger estimates, with 10 studies of LRTI re-
porting an increase in length of stay between 5.33 and 25.53
days,22-30 with a median increase of 9.35 days; 11 studies of
UTI revealed a median increase of 3.6 days (range, 0.5-6
days)24,25,28,31-36; and 2 studies of other infections reported in-
creases of 0 days24 and 2.5 and 7 days.2 One study37 that used
statistical regression methods attributed 8.4, 5.1, and 12.4
extra days of hospital stay to the occurrence of LRTI, UTI,
and other infections, respectively, whereas a second study38
reported an unadjusted difference of 25 days in the hospital
for each LRTI but used statistical regression to estimate an
adjusted additional cost of US $11,897 per LRTI.
The aim of the research reported here is to use statistical
regression to estimate the independent effect of HAI on
length-of-stay and cost outcomes in a cohort of hospitalized
patients. The method will avoid selection bias completely and
will address bias from omitted variables by including a com-
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prehensive set of explanatory terms in a statistical regression
model. We also aim to demonstrate that omitting important
variables from the statistical model causes bias in the costs
attributed to HAI. We conduct separate analyses for patients
who received a diagnosis of LRTI, UTI, or other HAI. We do
not, however, attempt to address the bias from endogenous
variables.
methods
Study Sites and Participants
We recruited participants from a 712-bed tertiary care referral
hospital and a 312-bed district hospital in southeast Queens-
land, Australia. Inclusion criteria were an age of 18 years or
older and a minimum inpatient stay of 1 night for the clinical
specialities listed in Table B1 in Appendix B. Patients were
identified from a routinely generated list of all admissions,
and patients with consecutive admissions were recruited from
both hospitals between October 13, 2002, and January 16,
2003, by 5 registered research nurses who worked at the ter-
tiary referral hospital and were seconded to collect the data
from both hospitals.
Data Collection
All variables for data collection were selected on the basis of
previous experience, expert opinion, and a review of the lit-
erature (the literature reviewed is listed in a Supplemental
Reading List that is available in the online edition of the
journal). Data collection tools were developed and then were
tested during a 10-week pilot study, and criteria for selecting
the values for all variables were established. This process in-
volved the research nurses, a senior infectious diseases phy-
sician, the project coordinator, and an epidemiologist with a
background in acute hospital services and infection control.
The result was an extensive data dictionary that summarized
definitions agreed to by the research team. This document
was the reference for any decision to assign a value to a
variable and is available from the authors on request. De-
mographic data were collected directly from the bedside by
use of “personal digital assistants” that linked to a custom-
designed Access database (Microsoft). After recruitment, data
collection was completed by a review of the patient’s medical
record, the hospital-based corporate information systems,
and the hospital pathology system, Auslab.39 Variables were
collected that described the demographic characteristics of
the sample, including the primary or most recent occupation
and education level, and a score of socioeconomic status was
derived via an algorithm described by Jones and McMillan.40
The length of hospital stay for each patient admitted was
calculated, and data were collected that described the con-
sumable items used by the patient. Market prices were then
applied to estimate the variable costs incurred during the
hospital stay. The type of admission (ie, elective, emergency,
or transfer), admission to a clinical unit, and all diagnosis
codes from the International Classification of Diseases and Re-
lated Health Problems, 10th Revision, Australian Modification41
were recorded. Any adverse events that occurred during the
hospital stay that might extend the stay were recorded, as
were all observable risk factors for HAI. Data cleaning was
undertaken alongside data collection by a separate researcher.
The data cleaner and research nurses worked together to en-
sure consistent application of definitions. All cases of HAI
were diagnosed using the Centers for Disease Control and
Prevention definitions modified for Australia42; when ambi-
guity existed, the senior infectious diseases physician was con-
sulted. The medical records of all patients with HAI and a
length of stay greater than 40 days were reviewed to identify
when, during the hospital stay, the infection was diagnosed,
was treated, and had cleared.
Statistical Methods
We used the generalized linear modeling (GLM) approach,
which employs maximum-likelihood estimation to summa-
rize the relationship between HAI and cost outcomes. Model
selection was based on testing whether the distributional as-
sumptions fit the data and which approach yielded the best
residuals; model selection is described in Appendix C. Six
models were specified to describe the relationship between
the 3 types of infection (UTI, LRTI, and other HAIs) and the
2 outcome variables (length of stay and variable costs). To
model length-of-stay outcomes, we chose a gamma distri-
bution to characterize the outcome and a log link function
to specify the relationship with the explanatory variables. To
model variable cost, we chose a gamma distribution with a
square-root link function. The gamma distribution is similar
in shape to the log-normal distribution45 and is robust to the
nonnormal distributions typical of length-of-stay and cost
outcomes.46-47 All coefficients were retransformed back to the
original units of length of stay (days) and variable costs
(AU$). We began with general models that included all avail-
able variables as explanatory terms, and variables were ex-
cluded because of multicollinearity, as assessed by nested aux-
iliary regression, where each variable in turn was dropped
from the model and the values were compared with2R
those of a complete model. We then sought a parsimonious
specification for each model by further reducing the model,
using backward stepwise regression with a 5% threshold for
statistical significance. SEs were made heteroskedasticity con-
sistent via the Huber-White covariance matrix, which was
applied in all estimation procedures.48 StataTM (Stata) was
used for all analyses.
We undertook further analyses of the parsimonious models
that described length-of-stay outcomes, to demonstrate the
bias from omitted variables. We removed variables from each
model, one by one, in no particular order, and compared the
parsimonious model with each restricted model. The likeli-
hood ratio (LR) test was used to assess the goodness of fit
between the 2 models and to make an inference about
whether the parsimonious model represented a better spec-
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ification of the relationship between HAI and the length-of-
stay outcome than did the artificially restricted models.
results
Overview of the Data
A total of 4,488 admissions were included in the study; 2,971
were admissions to the university teaching hospital, 1,640
were admissions for a surgical procedure, and 2,848 were
admissions for nonsurgical specialties. The mean age of pa-
tients was 58 years (range, 18-100 years), and 51% were male.
There were 228 cases of HAI diagnosed, giving an overall
incidence rate of 5.08% for the 95 days during which patients
were recruited. This included 37 LRTIs (incidence rate,
1.76%), 79 UTIs (incidence rate, 0.82%), and 49 other HAIs
(6 in the digestive system, 2 in the ear, 6 in the mouth and/
or esophagus, 1 in pleural fluid, 10 at an intravenous catheter
insertion site\, 18 involving skin, and 6 at an unknown site)
(incidence rate, 1.09%). The remaining 63 cases of infection
were excluded from the analyses and comprised surgical site
infections, bloodstream infections, and multiple infections.
Patients with HAI and Length of Stay Greater Than 40 Days
Of the 4,488 patients, 98 (2.2%) had a length of stay greater
than 40 days. Of these 98 patients, 10 received a diagnosis
of LRTI, 20 received a diagnosis of UTI, and 8 received a
diagnosis of other HAIs. For all but 1 of the patients with
LRTI and 2 of the patients with UTI, the HAI cleared early
in the stay (ie, within 12 days after admission), and other
factors were found that caused the long stay in hospital. In
particular, most of these patients were transferred to a re-
habilitation facility within the hospital to wait for placement
in a long-term residential care center; other reasons for long
stay were community-acquired bacteremia, serious medical
conditions, hypoxic brain injury, prolonged stay in the in-
tensive care unit, and slow recovery after surgery. Because
the extended hospital stay (140 days) was unrelated to the
episode of infection, those patients with a length of stay 140
days were excluded from the data set before the analyses were
done.
Unadjusted Comparison of Patients With HAI
and Patients Without
Patients without HAI were compared with patients with LRTI,
UTI, and other infections for selected variables, and the re-
sults are presented in Table 1. A list of all variables available
for analysis is included in Table B2 in Appendix B. Compared
with patients without HAI, patients with HAI were older,
stayed in the hospital longer, and incurred higher variable
costs. Fewer of them were discharged home, had elective ad-
missions, or were self-caring before hospital admission. A
higher proportion died in the hospital, experienced an adverse
event (eg, a fall, cardiac arrest, pressure ulcer, or gastroin-
testinal bleeding), presented with comorbidities (eg, anemia,
chronic obstructive pulmonary disease, congestive heart fail-
ure, diabetes, or underlying gastrointestinal or neurological
disease), and required an invasive device or procedure (eg,
catheterization, blood transfusion, oxygen therapy, or drain-
age tube).
Association Between HAI and Length of Hospital Stay,
Controlling for Multiple Variables
Three general models were specified to describe the relation-
ship between LRTI, UTI, and other HAIs and the length of
hospital stay. Six variables were removed from the general
models because of multicollinearity, which left 123 variables;
further reductions via the stepwise procedure resulted in par-
simonious models. In the UTI model, presence of UTI in-
fection was not a significant predictor of length of stay
( ); however, LRTI and other HAIs retained their sig-Pp .33
nificance in the parsimonious models, indicating that they
were associated with an increase in length of stay of 2.58 days
(95% confidence interval [CI], 1.80-3.69) and 2.61 days (95%
CI, 2.02-3.39), respectively. The Akaike information criterion
(AIC) statistic was 4.98 for the LRTI model that included 44
variables and was 4.97 for the model of other HAIs that
included 43 variables. The plot of the deviance residuals ver-
sus the predicted mean length of stay was not homoskedastic,
suggesting that the Huber-White SEs were necessary for both
models, and only 3 of the deviance residuals had values
greater than 3. A summary of the other variables that re-
mained significant in the parsimonious models and the es-
timates of the impact on length of stay are presented in Table
2. Many other factors alongside HAI were associated with
increases in length of stay—in particular, if patients were
transferred from another hospital or were admitted as emer-
gency case patients, if they smoked in the past or required
assistance for daily activities before admission, or if they were
admitted to the geriatric unit. Adverse events, such as falls
during the hospital stay, deep vein thrombosis, and anaphy-
lactic reactions, also increased length of stay, as did the use
of catheters, feeding devices, and drainage tubes. Underlying
risk factors, such as obesity, diabetes, previous stroke, malig-
nancy, and unresolved spinal injury, all increased length of
stay, as did dyspnea during the hospital stay, community-
acquired infection, fecal incontinence, and anemia.
Association Between HAI and Variable Costs, Controlling
for Multiple Variables
Three models were specified to describe the relationship be-
tween variable costs and LRTI, UTI, and other HAIs. No
variables were found to be multicollinear. The 3 general mod-
els included 129 variables that were reduced via the stepwise
procedure to generate parsimonious models. Neither UTI
( ) nor other infections ( ) were significantlyPp .18 Pp .11
associated with variable costs in the parsimonious models.
However, LRTI remained significant in the parsimonious
model, with an estimated cost increase of AU$24.04 (95%
table 1. Differences Between the Groups with Lower Respiratory Tract Infection (LRTI), Urinary Tract Infection (UTI), or Other
Healthcare-Acquired Infections (HAIs) and the Group Without HAI
Variable
Group without HAI
(np 4,230)
Group with LRTI
(np 27)
Group with UTI
(np 59)
Group with Other HAIs
(np 41)
Length of hospital stay, mean d  SD 4.80  5.01 15.19  8.32 14.86  10.52 15.49  11.41
Cost outcomes, mean AU$  SD
Variable costs—drugs 100.61  471.95 963.70  1,842.56 139.29  143.01 1,022.34  3,380.29
Variable costs—other 21.21  58.03 133.19  209.23 37.66  173.57 120.27  284.21
Variable costs—total 121.77  486.90 1,097.00  1,887.51 176.93  276.22 1,142.61  3,395.30
Demographic and social characteristics
Age at admission, mean y  SD 56.90  20.02 67.00  14.04 71.59  19.20 64.93  18.49
Socioeconomic status score (range, 0-100), mean  SD 37.23  21.39 44.40  24.92 32.33  20.53 38.08  25.39
Male 2,177 (51.47) 19 (70.37) 18 (30.51) 22 (53.66)
White 3,872 (91.55) 26 (95.83) 56 (94.55) 38 (91.89)
Current drinker 2,635 (62.30) 19 (70.83) 26 (44.06) 24 (58.61)
Current smoker 1,058 (25.01) 4 (13.15) 14 (22.96) 3 (6.97)
Self-caring before admission 3,024 (71.49) 15 (54.17) 23 (39.29) 24 (58.97)
Obese 3,164 (74.81) 24 (87.99) 49 (83.78) 33 (81.70)
Admission, hospital stay, and discharge characteristics
Discharged to home 4,022 (95.08) 19 (70.37) 44 (74.58) 29 (70.73)
Died in hospital 88 (2.08) 6 (22.22) 8 (13.56) 7 (17.07)
Elective admission 1,833 (43.33) 8 (29.63) 19 (32.20) 14 (34.15)
Stay was in teaching hospital 2,763 (65.32) 25 (92.59) 42 (71.19) 30 (73.17)
Adverse events during hospital stay
Fall 56 (1.32) 2 (7.41) 6 (10.17) 2 (4.88)
Cardiac arrest 105 (2.48) 6 (22.22) 8 (13.56) 7 (17.07)
Pulmonary embolus 5 (0.12) 2 (7.41) 1 (1.69) 0
Pressure ulcer 130 (3.07) 7 (25.93) 8 (13.56) 6 (14.63)
Gastrointestinal bleeding 187 (4.42) 7 (25.93) 4 (6.78) 6 (14.63)
Comorbidities
Fecally incontinent 221 (5.22) 8 (29.63) 17 (28.81) 9 (21.95)
Anemic at admission 753 (17.80) 12 (44.44) 20 (33.90) 12 (29.27)
Anemic during hospital stay 1,603 (37.90) 25 (92.59) 42 (71.19) 29 (70.73)
Admitted with fracture or dislocation 225 (5.32) 4 (14.81) 10 (16.95) 2 (4.88)
Chronic obstructive pulmonary disease 447 (10.57) 7 (25.93) 12 (20.34) 5 (12.20)
Cirrhosis of the liver 48 (1.13) 1 (3.70) 0 3 (7.32)
Congestive heart failure 269 (6.36) 4 (14.81) 8 (13.56) 4 (9.76)
Coronary artery disease 585 (13.83) 3 (11.11) 6 (10.17) 6 (14.63)
Diabetes 668 (15.79) 9 (33.33) 20 (33.90) 7 (17.07)
Underlying gastrointestinal disease 1,273 (30.09) 14 (51.85) 26 (44.07) 13 (31.71)
Underlying neurological disease 446 (10.54) 7 (25.93) 27 (45.76) 12 (29.27)
Ever had a stroke 290 (6.86) 3 (11.11) 12 (20.34) 8 (19.51)
Hypertension 1,461 (34.54) 12 (44.44) 30 (50.85) 17 (41.46)
Dyspnea 1,047 (24.75) 18 (66.67) 22 (37.29) 15 (36.59)
Hyponatremic at admission 340 (8.04) 4 (14.81) 16 (27.12) 7 (17.07)
Multitrauma 6 (0.14) 0 0 1 (2.44)
Neurogenic bladder 12 (0.28) 1 (3.70) 1 (1.69) 1 (2.44)
Peripheral pulses absent 55 (1.30) 2 (7.41) 0 2 (4.88)
Device, procedure, and/or therapy received
Urinary catheter 1,073 (25.37) 19 (70.37) 45 (76.27) 17 (41.46)
Arterial catheter 532 (12.58) 9 (33.33) 6 (10.17) 10 (24.39)
Central venous catheter 259 (6.12) 8 (29.63) 2 (3.39) 10 (24.39)
Epidural or intrathecal catheter 131 (3.10) 2 (7.41) 5 (8.47) 3 (7.32)
Indwelling or suprapubic urinary catheter 1,041 (24.61) 19 (70.37) 43 (72.88) 16 (39.02)
Instrumentation of bladder 144 (3.40) 1 (3.70) 4 (6.78) 0
Intracranial pressure monitor 5 (0.12) 1 (3.70) 1 (1.69) 1 (2.44)
Peripheral parenteral device 3,797 (89.76) 26 (96.30) 56 (94.92) 36 (87.80)
Transfusion of blood and/or blood products 394 (9.31) 11 (40.74) 14 (23.73) 19 (46.34)
Parenteral nutrition 10 (0.24) 0 0 4 (9.76)
Oxygen therapy 2,837 (67.07) 26 (96.30) 45 (76.27) 32 (78.05)
Nasogastric tube 317 (7.49) 13 (48.15) 12 (20.34) 12 (29.27)
Pleural drainage 692 (16.36) 8 (29.63) 11 (18.64) 16 (39.02)
Drain tube of any type 1,447 (34.21) 15 (55.56) 24 (40.68) 14 (34.15)
Anticoagulant therapy 480 (11.35) 8 (29.63) 4 (6.78) 6 (14.63)
Nonsteroid antiinflammatory therapy 1,584 (37.45) 11 (40.74) 30 (50.85) 16 (39.02)
Stress ulcer prophylaxis 1,287 (30.43) 21 (77.78) 26 (44.07) 22 (53.66)
Patient unable to protect airway from aspiration 1,530 (36.17) 17 (62.96) 25 (42.37) 20 (48.78)
note. Data are no. (%) of patients, unless otherwise indicated.
table 2. Results of Generalized Linear Modeling Statistical Regression Models Under the Assumption of the
Gamma Distribution That Describe the Association Between Length of Hospital Stay and Lower Respiratory Tract
Infection (LRTI) and Other Healthcare-Acquired Infections (HAIs)
Variable
LRTI
Coefficienta (95% CI), days
Other HAI
Coefficientb (95% CI), days
HAI and general factors
HAI (either LRTI or other) 2.58 (1.80-3.69) 2.61 (2.02-3.39)
Emergency admission 2.23 (1.90-2.61) 2.12 (1.81-2.48)
Interhospital transfer 2.57 (2.13-3.10) 2.48 (2.06-2.99)
Some assistance required before admission 2.24 (1.93-2.61) 2.19 (1.89-2.55)
Ex-smoker 1.76 (1.53-2.02) 1.72 (1.50-1.98)
Age (155 y) NS 2.05 (1.77-2.38)
Admitted to geriatric unit 0.97 (0.78-1.22) 0.91 (0.66-1.27)
Adverse events during hospital stay
Any adverse event 2.90 (2.43-3.48) 2.78 (2.31-3.34)
Two falls 2.92 (1.80-4.76) 2.87 (1.74-4.74)
Deep vein thrombosis 2.81 (1.78-4.42) 2.83 (1.79-4.48)
Peripheral pulses absent 2.79 (2.12-3.67) 2.70 (2.06-3.55)
Anaphylactic reaction 0.98 (0.79-1.21) 1.02 (0.82-1.26)
Gastrointestinal bleeding 1.36 (1.09-1.70) 1.36 (1.09-1.70)
Devices, therapies, and/or interventions
Central venous catheter in situ during hospital stay 2.41 (1.98-2.93) 2.33 (1.92-2.83)
Unable to protect airway from aspiration NS 1.67 (1.42-1.96)
Indwelling or suprapubic urinary catheters during hospital stay 2.28 (1.96-2.66) 2.26 (1.94-2.63)
Parenteral nutrition during hospital stay 2.88 (1.99-4.16) 2.46 (1.75-3.45)
Received stress ulcer prophylaxis 2.14 (1.85-2.46) 2.10 (1.82-2.41)
Nasogastric tube in situ during hospital stay 2.36 (1.96-2.83) 2.35 (1.96-2.82)
Drain tube of any type during hospital stay 2.48 (2.10-2.91) 2.40 (2.05-2.82)
Nonsteroid antiinflammatory therapy 1.98 (1.72-2.29) 1.94 (1.69-2.24)
Anti-coagulant therapy during hospital stay 2.45 (2.08-2.89) 2.41 (2.05-2.84)
Intracranial pressure monitor in situ during hospital stay 1.24 (0.91-1.70) 1.18 (0.86-1.60)
Comorbid conditions (chronic)
Unresolved spinal injury 1.19 (0.80-1.76) 1.19 (0.79-1.77)
History of stroke 2.24 (1.82-2.75) 2.19 (1.78-2.70)
Malignancy 2.03 (1.72-2.39) 2.00 (1.69-2.35)
Coronary artery disease 1.49 (1.27-1.75) 1.45 (1.23-1.70)
Obesity 1.74 (1.50-2.02) 1.71 (1.47-1.98)
Diabetes 1.98 (1.68-2.34)c 1.94 (1.65-2.29)c
Underlying urinary tract disease 2.02 (1.72-2.38) 1.98 (1.69-2.33)
History of organ transplant 1.55 (1.01-2.37)c 1.41 (0.96-2.08)c
Comorbid conditions (acute)
Dyspnea during hospital stay 2.06 (1.78-2.38) 2.05 (1.77-2.37)
Admitted with fracture or dislocation 2.66 (2.10-3.38) 2.25 (1.71-2.97)
Community-acquired infection 2.27 (1.92-2.67) 2.21 (1.87-2.60)
Fecally incontinent during hospital stay 2.52 (2.06-3.09) 2.47 (2.02-3.02)
Anemic at admission 1.68 (1.42-1.99) 1.65 (1.40-1.95)
Anemic during hospital stay 2.63 (2.25-3.06) 2.55 (2.19-2.97)
ICD-10-AM disease classification
Diseases of skin and subcutaneous tissue 2.53 (1.88-3.40) 2.54 (1.90-3.41)
Diseases of musculoskeletal system and connective tissue 2.14 (1.73-2.65) 2.19 (1.77-2.71)
Pregnancy, childbirth, and puerperium 2.22 (1.81-2.71) 2.21 (1.80-2.70)
Injury, poisoning, and external causes NS 2.23 (1.79-2.78)
Endocrine, nutritional, and metabolic diseases 2.14 (1.71-2.67) 2.13 (1.71-2.66)
Diseases of the nervous system 2.41 (1.82-3.19) 2.39 (1.80-3.16)
Diseases of ear and mastoid process 1.22 (0.89-1.67) 1.24 (0.91-1.70)
Constant in model 3.46 (2.90-4.14) 3.30 (2.76-3.94)
note. The outcome variable was length of hospital stay, in days. Data were significant at the 5% level unless indicated otherwise.
AIC, Akaike information criterion; BIC, Bayesian information criterion; ICD-10-AM, International Classification of Diseases and
Related Health Problems, 10th Revision, Australian Modification; NS, variable was not significant at 5% and removed during stepwise
variable selection process.
a No. of observations p 3,833; deviance p 1,656; AIC p 4.98; BIC p 29,599.
b No. of observations p 3,833; deviance p 1,644; AIC p 4.97; BIC p 29,603.
c Data were significant at the 10% level.
table 3. Results of Generalized Linear Modeling Statistical Regression Models Under the As-
sumption of the Gamma Distribution That Describe the Association Between Variable Costs and
Lower Respiratory Tract Infection (LRTI)
Variable
LRTI
Coefficienta (95% CI), $
Infection and general characteristics
LRTI 24.04 (10.15-43.46)b
Obesity 6.46 (4.69-8.47)b
Current smoker 6.72 (4.08-9.90)
Ex-smoker 6.97 (4.46-9.95)
Current drinker 5.92 (3.58-8.75)
More than 1 admission in data set 5.43 (3.25-8.06)b
Torres Straight Islander 5.46 (1.88-10.47)
Full assistance required before admission 4.38 (1.55-8.24)b
Patient admitted to 1 of study hospitals in previous 12 mo 7.40 (4.83-10.45)b
Adverse events
One fall during hospital stay 12.95 (7.85-19.21)b
Two falls during hospital stay 17.75 (9.62-28.18)b
Three or more falls during hospital stay 20.83 (8.60-38.01)b
Deep vein thrombosis during hospital stay 11.79 (5.60-20.03)b
Anaphylactic reaction during hospital stay 19.35 (14.01-25.50)b
Peripheral circulation compromised as a result of pulmonary embolus 10.19 (4.63-17.64)c
Cardiac arrest during hospital stay 9.79 (5.44-15.25)b
Epilepsy or any seizure of unknown origin 7.71 (4.46-11.71)c
Devices, therapies, and/or interventions
Drain tube of any type during hospital stay 8.43 (5.83-11.46)b
Transfusion of blood and/or blood products 15.80 (10.14-22.62)b
Oxygen therapy during hospital stay 6.52 (3.80-9.84)
Nasogastric tube in situ during hospital stay 6.87 (4.22-10.06)
Peripheral parenteral device in situ during hospital stay 10.86 (7.31-15.05)b
Intracranial pressure monitor in situ during hospital stay 15.13 (8.84-22.97)b
Arterial catheter in situ during hospital stay 9.68 (6.05-14.06)b
Central venous catheter in situ during hospital stay 10.80 (7.21-15.05)b
Epidural or intrathecal catheter in situ during hospital stay 9.27 (6.26-12.80)b
Nonsteroid antiinflammatory drugs (eg, aspirin) received during hospital stay 7.76 (5.19-10.77)b
Received stress ulcer prophylaxis (eg, Ranitidine) 6.85 (4.43-9.71)
Anticoagulant therapy during hospital stay 7.16 (4.30-10.63)
Patient unable to protect airway from aspiration 6.49 (3.98-9.52)
Comorbid condition (chronic)
Cirrhosis of the liver 3.71 (0.97-7.64)b
Comorbid conditions (acute)
Anemic at admission 5.12 (2.88-7.87)b
Community-acquired infection 8.26 (5.59-11.40)b
Anemic during hospital stay 7.60 (5.04-10.62)b
Dyspnea during hospital stay 7.17 (4.38-10.54)
ICD-10-AM disease classification
Disease of digestive system 5.27 (3.07-7.93)b
Diseases of skin and subcutaneous tissue 8.01 (4.09-13.04)
Diseases of genitourinary system 4.10 (2.02-6.72)b
Pregnancy, childbirth, and puerperium 1.65 (0.02-4.03)b
Symptoms, signs, and abnormal clinical and/or laboratory findings 2.88 (0.96-5.46)b
Neoplasms 4.83 (2.60-7.60)
Factors influencing health status 5.08 (2.40-8.54)c
Constant 28.50 (21.62-36.29)
note. The outcome variable was costs in AU$. AIC, Akaike information criterion; CI, confidence interval;
ICD-10-AM, International Classification of Diseases and Related Health Problems, 10th Revision, Australian
Modification.
a No. of observations p 3, 795; deviance p 5,155; AIC p 11.10.
b Data were significant at the 5% level.
c Data were significant at the 10% level.
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figure 1. An illustration of bias from omitted variables in models that describe the relationship between lower respiratory tract infection
(LRTI) or other healthcare-acquired infections (HAIs) and additional length of hospital stay.
CI, $10.15-$43.46) per LRTI (approximately US $17.58 [95%
CI, $7.42-$31.79]). The AIC statistic was 11.1 for the model
that included 45 variables. The plot of the deviance residuals
versus the predicted mean length of stay was not homoske-
dastic, suggesting that the Huber-White SEs were necessary,
and 41 of the deviance residuals had values greater than 3.
A summary of the variables that remained significant in the
parsimonious model for LRTI, along with their estimated
effect on variable costs, is presented in Table 3. Many other
factors alongside LRTI were associated with increased variable
costs.
Bias from Omitted Variables and Length of Stay
Outcomes
To explore what might happen if information on a smaller
number of confounders was available for the analyses, we
removed variables related to length of stay from the models
for LRTI and for other HAIs. As variables were removed, the
fit of the models deteriorated. When the parsimonious model
for LRTI was compared with a restricted model that had 1
variable omitted, the result of the LR test showed that the
omitted variable made a valid contribution to the explanatory
power of the model ( ; ), in-2LR x (1 df)p 3.54 Pp .0598
dicating at the 5% significance threshold that there was mar-
ginal evidence for the restricted model (ie, the model with 1
omitted variable). The interpretation is that the unrestricted,
or parsimonious, model provides a superior description of
the relationship between LRTI and length of stay. When the
parsimonious model for other HAIs was compared with a
restricted model with 1 variable omitted, the same conclusion
was drawn ( ; ). As more var-2LR x (1 df)p 3.38 Pp .0660
iables were omitted, the x2 statistic increased, suggesting that
the model specifications continued to deteriorate. The co-
efficient for LRTI and other HAIs increased as more variables
were removed, suggesting a positive bias from omitted var-
iables. The extent of the bias is illustrated in Figure 1, where
the number of variables included in the model is plotted along
the X-axis and the length of stay attributable to LRTI and
other HAIs, as estimated by the model, is plotted along the
Y-axis.
discussion
These data suggest that patients who developed an HAI stayed
longer in the hospital and incurred greater variable costs. This
is no great surprise, because the patients with HAI were older,
sicker, and required more clinical interventions; more of them
were unable to care for themselves before admission; more
of them died in the hospital; and more of them did not return
to their own homes after discharge. After controlling for a
comprehensive set of confounders, we found that LRTI is
associated with an increase in length of stay of 2.58 days and
with variable costs of AU$24 (approximately US $17),
whereas other HAIs are associated with an increase in length
of stay of 2.61 days but no increase in variable costs. UTI
did not increase length of hospital stay or variable costs. We
found many other variables that were important for explain-
ing the relationship between HAI and cost outcomes, and the
omission of these variables causes a positive bias in the es-
timated length of stay attributed to HAI.
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Although these results contradict those reported in the
existing literature, we believe they are less biased. The first
part of our argument is that we specified a good statistical
model. The method avoided selection bias by controlling for
confounding in the analysis stage rather than in the design
stage and reduced bias from omitted variables by including
a comprehensive set of control variables. We also suggest that
the GLM model using a log link function is more appropriate
than an ordinary least squares regression on a log-trans-
formed outcome, and we provide a review of model selection
in Appendix C. The second part of our argument is that these
results are clinically intuitive. In our experience, few hospital
physicians believe that a single UTI independently increases
length of hospital stay and that patients with HAI often dem-
onstrate multiple health problems that predispose them to a
longer stay regardless of the type of HAI. The third part of
our argument is that, when variables were excluded from the
parsimonious model, the quality of the model deteriorated
and the estimates of length of stay attributable to HAI in-
creased and were biased. Box A marked in Figure 1 sum-
marizes the characteristics of the existing published research
that used 4-12 control variables and estimated outcomes at
5-11 days of stay due to HAI. The existing studies are superior
to an unadjusted comparison, which estimates attributable
length of stay at 12.5 days for LRTI and 14 days for other
HAIs, but we demonstrate that inclusion of a comprehensive
set of control variables produces a lower estimate of attrib-
utable length of stay.
We believe that length of stay and variable costs are the
appropriate outcomes to describe the economic cost of HAI.
The reasons have been discussed elsewhere,9 but we review
the argument here. Between 80% and 90% of the costs of
running a hospital are fixed in the short term,49,50 and the
short term is generally the time frame in which decisions
about investments in infection control are made. The finan-
cial expenditures made for fixed costs, as recorded by the
hospital’s cost accountants, are important for those who man-
age the cash flow and financial viability of the hospital. How-
ever, they are largely irrelevant for economic analysis and
decision making in the short term, because these expenditures
for fixed costs will not change with rates of HAI. A more
useful measure on which to base decisions about additional
investment in infection control is the number of bed-days
used for HAIs, and the monetary value of these bed-days
depends on their value for alternate uses (ie, the revenue
from providing treatment to newly admitted patients). In
contrast, expenditures for variable costs, such as dressings,
drugs, fluids, gloves, gowns, and other consumables used by
HAI, will change with rates of HAI; however, these items are
much lower in value compared with the high fixed overheads
typical of healthcare organizations.51-53 Because the main rea-
son we wish to understand the cost of HAI is to demonstrate
how costs will change with increased investments in infection
control, we should concentrate on measuring the cost out-
comes that change rather than those that do not; therefore,
data from the cost-accounting department of a hospital that
describe expenditures for fixed costs are not useful. Length-
of-stay data and expenditure for variable costs are more use-
ful, as well as easier to procure and interpret.
There are weaknesses of this study; for example, we did
not address any possible interactions between control var-
iables, nor did we address the problem of bias from endog-
enous variables. We do not believe, however, that the inclu-
sion of interaction terms will make substantial improvements
on the parsimonious model, and the complexities of bias from
endogenous variables are probably best dealt with in separate
analyses.
Our estimates of the cost of HAI are lower than those
reported in the existing literature. We encourage other re-
search groups to collect data to test the predictors in our
models and either validate or refute our findings. We sincerely
hope that these results are received with interest and enthu-
siasm by the infection control community. A perception that
this work is anti–infection control and is an attempt to down-
play the size of the problem represented by HAI is incorrect;
our intention is the polar opposite. Biased and inflated es-
timates of the costs of HAI might have short-term impact,
but, when decision makers undertake a critical examination
of the research and find methods that may lead to bias and
subsequently to results that do not make intuitive sense, then
the infection control community risks the loss of credibility.
Furthermore, the likelihood of further investments in infec-
tion control may diminish as a result. More useful are valid
estimates of the cost of HAI that are then applied in appro-
priately designed decision-analytic economic models that will
make valid and believable predictions of the economic value
of infection control. There is no doubt that existing infection
control is an essential activity and that more infection control
than current levels is likely to return a favorable ratio of cost
to benefit, compared with other investments in healthcare
services. However, the economic arguments must be made
properly with good quality data, and the results should be
targeted at key decision makers at the local, state, and federal
levels. This should be the aim of those who lobby for increases
in investments in infection control.
Address reprint requests to Nicholas Graves, PhD, School of Public Health,
Queensland University of Technology, Victoria Park Rd., Kelvin Grove, QLD
4059, Australia (n.graves@qut.edu.au).
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appendix a
Description of Bias From Omitted Variables
If the true model is and theY p a  a X  a Z  ut 0 1 t 2 t
model is estimated, then the omitted var-Y p b  b X  ut 0 1 1
iable can be thought of as a function of X in an auxiliary
regression, . So, it has been estimatedZ p g  g X  w1 0 1 t t
that , orY p b  b X  b (g  g X  w ) ut 0 1 1 2 0 1 t t t
Y p (b  b g ) (b  g b )X  (b w  u )t 0 2 0 1 1 2 t 2 t t
Y p d  d X   .t 0 1 t t
So, unless ,ˆb p E(b )( 02 1
 x zt t
ˆE(b )p b  b .1 1 2( )2 x t
There will be a bias as the coefficient of X picks up part of
the influence of Z that was correlated with X, and it can be
concluded that (1) the coefficient estimate can have a positive
or negative bias, (2) its standard error will also be biased
positively, and (3) the bias on the coefficient can either cancel
or reinforce the bias in the standard error when a t test is
done.
The source of the material presented in Appendix A is the
Applied Research in Economics Group (http://carecon.org.
uk/) at the University of the West of England in Bristol,
United Kingdom.
appendix b
table b1. Clinical Specialties From Which Patients Were Re-
cruited
Breast endocrine and thoracic
Cardiac surgical unit
Cardiology
Colorectal
Diabetes/endocrine
Ear nose and throat
Gastroenterology
General medicine
Geriatric
Gynecology
Hepato-pancreato-biliary
Infectious diseases
Intensive care unit
Medical stroke unit
Neurology
Orthopedic
Respiratory
Rheumatology
General surgical unit
Upper gastrointestine and soft tissue
Urology
Vascular
Women’s and children’s health
table b2. All Variables Included in the Data Collection and
Available for Analyses
This table is available in its entirety in the online
edition of Infection Control and Hospital Epidemiology.
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figure C2. SEs of from gamma GLM with log link andE(yFx)
from ordinary least squares.E(yFx) ln (y)
figure C1. Plot of the residuals versus the fitted values with
Lowess smoother of ordinary least squares.ln (y)
appendix c
Notes on Model Selection: GLM Versus ln(y) Ordinary
Least Squares
In Figure C1, we present the plot of the residuals versus fitted
values with Lowess smoother of with ordinary leastln (y)
squares. This suggests heteroskedasticity and implies either
the implementation of a suitable GLM model or retransfor-
mation by estimation of the log-scale variance function
. The log-scale residuals were slightly leptokurtic (coef-n(x)
ficient of kurtosis, 3.20). Because the log-scale residuals were
heteroskedastic and somewhat leptokurtic, the performance
of the GLM and ordinary least squares with hetero-ln (y)
skedasticity transformation were compared for precision. The
modified Park test was used to determine the relationship
between the raw-scale mean and the raw-scale variance for
a suitable GLM model. The ordinary least squares version
of the modified Park test is described by Manning and
Mullahy43; , where2ˆ ˆ ˆln (y  y ) p l  l ln (y ) n y pi i 0 1 i i i
from the GLM specification. The estimate of theˆexp (x b)i
coefficient l1 on the log of the raw-scale prediction indicated
the type of GLM to be employed. The coefficient l p1
supported the gamma family because l1 was not sig-1.93
nificantly different from 2, ( ). The data2x (1)p 0.64 Pp .42
in Figure C2 demonstrate that the SEs of the gamma GLM
(median, 0.09 [range, 0.00-0.45]) and the ordinary leastln (y)
squares (median, 0.08 [range, 0.04-0.49]) were very similar,
with a median difference of .008 in favor of the marginally
more precise ordinary least squares. However, theln (y)
gamma GLM with log link was preferred because of the ease
of expressing the expected outcome, ; the difficulty inE(yFx)
retransforming the ordinary least squares to accountln (y)
for heteroskedasticity is described by Willard Manning.44
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